Amgen is to invest $1 billion into a second drug substance manufacturing facility in North Carolina, bringing the company’s total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.

The facility will incorporate technologies and sustainable practices, and is intended to play a key role in Amgen’s global manufacturing network.